Navigation Links
ARIUS announces five abstracts selected for presentation at 2008 AACR Annual Meeting
Date:2/26/2008

TORONTO, Feb. 26 /PRNewswire-FirstCall/ - ARIUS Research Inc., (TSX: ARI), a biotechnology company discovering and developing the next wave of antibody therapeutics, today announced that five abstracts have been selected for presentation at the American Association for Cancer Research (AACR) Annual Meeting held from April 12-16, 2008 in San Diego, California. The Company will deliver presentations that will disclose new findings about its CD44, TROP-2, CD59, and CD9 antibody programs.

"The inclusion of five ARIUS abstracts in this conference is a significant achievement, demonstrating the scientific community's interest in our programs and the high quality of our research," said Dr. David Young, President and CEO. "Among these abstracts are findings from our cancer stem cell programs targeting CD44 and CD9. This is an exciting new area of cancer research and as we prepare our CD44 antibody to enter human clinical trials this year, we believe we will have one of the only novel cancer stem cell drugs entering clinical trials in the near-term."

The following ARIUS' abstracts will be presented:

Abstract Number 3975:

"Preclinical development of huARH460-16-2, a humanized antibody to the CD44 cancer stem cell target." Experimental and Molecular Therapeutics 32, Tuesday, April 15, 2008, 8:00 AM

Abstract Number 3976:

"Anti-CD44 antibody, ARH460-16-2, binds to human AML CD34+CD38- cancer stem cells and demonstrates anti-tumor activity in an AML xenograft model." Experimental and Molecular Therapeutics 32, Tuesday, April 15, 2008, 8:00 AM

Abstract Number 3990:

"AR47A6.4.2, a naked monoclonal antibody targeting Trop-2, exhibits anti-tumor efficacy in multiple human cancer models as a monotherapeutic agent and demonstrates efficacy in combination therapy." Experimental and Molecular Therapeutics 32, Tuesday, April 15, 2008, 8:00 AM

Abstract Number 3993:

"Anti-CD9 antibody, AR40A746.2.3, inhibits tumor
'/>"/>

SOURCE ARIUS Research Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ARIUS presents new findings showing therapeutic antibody inhibits human leukemic cancer stem cells
2. Laureate Announces Manufacturing Agreement with ARIUS for Trop-2 Targeting Antibody
3. ARIUS announces manufacturing Agreement with Laureate Pharma For Trop-2 targeting antibody
4. ARIUS announces fourth quarter and year-end fiscal 2007 financial results
5. Arius completes Pre-IND Meeting with FDA for Lead CD44 Cancer Stem Cell Program
6. ARIUS to Hold Fourth Quarter and Year End 2007 Conference Call
7. ARIUS announces manufacturing agreement with Avid Bioservices for CD44 Cancer Stem Cell antibody
8. ARIUS to present at BioNorth Biotechnology and Life Sciences Conference
9. Arius announces new findings in Trop-2 and CD59 CANCER antibody programs
10. ARIUS announces cancer stem cell antibody program successfully completes first toxicology study
11. ARIUS to present at Chinese Global Financial Forum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... 26, 2015 On behalf of biotech ... companies, Wilentz, Goldman & Spitzer, P.A. (Wilentz) ... lawsuit against Genewiz Inc. in excess of $10 million. ... GenScript’s trade secrets, and that it improperly hired one ... an order denying motions for judgment notwithstanding the verdict, ...
(Date:2/26/2015)... IL (PRWEB) February 26, 2015 Already ... its gauging line by expanding its Length Gauge offerings ... ACANTO gauges. , Specifically, HEIDENHAIN’s pencil probe-style ... improved force specification. Two new 1Vpp, 12mm stroke ... lower force applications. One is a variant with a ...
(Date:2/26/2015)... Regis Technologies announced new potent compound ... substances. , Regis Technologies is proud to announce the ... Suite (PCS) for 2015. , Regis is a contract ... in Morton Grove, Illinois. The PCS addition will provide ... to about one kilogram per batch. , Regis’ ...
(Date:2/26/2015)...  Spark Therapeutics (NASDAQ: ONCE ) announced ... in the Cowen and Company Health Care Conference on ... the Boston Marriott Copley Place. To access ... the Cowen conference, please visit the "Upcoming Events" section ... Therapeutics website at www.sparktx.com .  A replay of ...
Breaking Biology Technology:Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 3Accuracy and Versatile Gauging Go Hand in Hand at HEIDENHAIN 2Regis Extends cGMP Services to Oncology Market 2Spark Therapeutics to Participate in the 35th Annual Cowen and Company Health Care Conference 2
... HILL, N.C., Nov. 5 As biopharmaceutical,companies ... considerable efforts,are placed on strategy and execution ... focus on revenue growth and little else. ... excellence, a recent study,was conducted by Best ...
... - Phase II PC-DAC(TM):Exendin-4 Data in December - ... MONTREAL, Nov. 5 /PRNewswire-FirstCall/ - ConjuChem Biotechnologies,Inc. (TSX:CJB) ... Phase II,clinical trial of PC-DAC(TM):Exendin-4. This Phase II ... that,evaluated the efficacy and safety of three months ...
... BioMarin,Pharmaceutical Inc. (Nasdaq: BMRN ) today announced ... a company,update at the Credit Suisse 2008 Annual Healthcare ... 10:30 a.m. MST., Interested parties may access a ... section of the BioMarin website, http://www.BMRN.com .,A replay ...
Cached Biology Technology:New Study Provides Key Findings for Biopharma Product Launch Evaluation 2ConjuChem Provides Development Update 2ConjuChem Provides Development Update 3BioMarin to Present at the Credit Suisse Healthcare Conference 2
(Date:1/22/2015)... , Jan. 13, 2015 /PRNewswire/ - Today, FindBiometrics, the leading source ... launch of its new website design. "When we ... infancy", says Peter O,Neill , founder and CEO of ... industry needs involvement from the key players on a very ...
(Date:1/22/2015)... , Jan. 15, 2015  BellBrook Labs, a leader ... announced the launch of a TR-FRET (time resolved ... Transcreener UDP Assay, a high throughput screening assay ... assay will allow for sensitive detection of hundreds ...
(Date:1/22/2015)... POINT ROBERTS, Washington , January 20, 2015 ... including technology and tech stocks, releases video from the CES ... and security consultant Apollo Robbins . Apollo ... the Wocket™ biometric smart wallet, a product of NXT-ID, Inc. ...
Breaking Biology News(10 mins):Identity Industry Leading Publication Debuts New Look As Biometrics Hit Mainstream 2BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 2Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 3
... recent study to be published on April 27, 2011, in ... Hazen and colleagues found that oceanographic and prey measurements can ... team from Duke University, Woods Hole, and the Naval Undersea ... features and distributions of prey off the east coast of ...
... add new functions to stainless steel and make it ... by an interdisciplinary team at the University of Alberta ... was developed to address some of the problems associated ... body. Implanted biomedical devices, such as cardiac stents, ...
... CORVALLIS, Ore. - They can be both a blessing and a ... species are found from mountain tops to smoking volcanic vents on the ... to support much of the plant and animal life on Earth. ... And to a large extent, no one cared. Such has been the ...
Cached Biology News:Identifying beaked whale foraging habitat in the tongue of the ocean, Bahamas 2Sweet chemistry: Carbohydrate adhesion gives stainless steel implants beneficial new functions 2Research outlines mysterious evolution of nematodes -- one of Earth’s first animals 2Research outlines mysterious evolution of nematodes -- one of Earth’s first animals 3
Mouse monoclonal [X223] to Lamin B1 + B2 - Nuclear Envelope Marker ( Abpromise for all tested applications). entrezGeneID: 4001 SwissProtID: P20700...
odz, odd Oz/ten-m homolog 1 [Source:RefSeq_peptide;Acc:NP_055068] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Rabbit polyclonal to NIRF ( Abpromise for all tested applications). Antigen: Synthetic peptide derived from residues 186-235 of human NIRF. Entrez Gene ID: 115426 Swiss Protein ID: Q96PU...
Rabbit polyclonal to ZNF261 ( Abpromise for all tested applications). entrezGeneID: 9203 SwissProtID: Q14202...
Biology Products: